[{"id":"56bb338a-9a55-47ed-87d8-9a54d97136da","acronym":"","url":"https://clinicaltrials.gov/study/NCT03595124","created_at":"2021-01-18T17:40:40.562Z","updated_at":"2025-02-25T16:31:25.872Z","phase":"Phase 2","brief_title":"A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC)","source_id_and_acronym":"NCT03595124","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD8 • PD-1 • CD38 • PTPRC • CD69 • TFE3 • CD14 • CD24 • ITGAM • FOXP3","pipe":" | ","alterations":" PD-L1 expression","tags":["CD8 • PD-1 • CD38 • PTPRC • CD69 • TFE3 • CD14 • CD24 • ITGAM • FOXP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • axitinib • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 01/08/2019","start_date":" 01/08/2019","primary_txt":" Primary completion: 09/30/2024","primary_completion_date":" 09/30/2024","study_txt":" Completion: 01/23/2026","study_completion_date":" 01/23/2026","last_update_posted":"2025-02-07"},{"id":"e0be9b49-8cbc-4688-a452-7aaedd1a1b20","acronym":"","url":"https://clinicaltrials.gov/study/NCT05228015","created_at":"2022-02-12T17:47:53.327Z","updated_at":"2024-07-02T16:35:09.961Z","phase":"Phase 1","brief_title":"Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects With Advanced Solid Tumors","source_id_and_acronym":"NCT05228015","lead_sponsor":"Ikena Oncology","biomarkers":" YAP1 • TFE3 • CAMTA1 • TAFAZZIN","pipe":" | ","alterations":" TFE3 fusion","tags":["YAP1 • TFE3 • CAMTA1 • TAFAZZIN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TFE3 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • IK-930"],"overall_status":"Recruiting","enrollment":" Enrollment 198","initiation":"Initiation: 01/07/2022","start_date":" 01/07/2022","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2024-04-12"},{"id":"f8beb39f-22d1-4bc0-8c73-5790f2f0aa80","acronym":"","url":"https://clinicaltrials.gov/study/NCT05808608","created_at":"2023-04-11T14:03:45.332Z","updated_at":"2024-07-02T16:35:35.848Z","phase":"Phase 1/2","brief_title":"A Study of AK104 Plus Axitinib in Advanced/Metastatic Special Pathological Subtypes of Renal Cell Carcinoma","source_id_and_acronym":"NCT05808608","lead_sponsor":"Hao Zeng","biomarkers":" TFE3","pipe":"","alterations":" ","tags":["TFE3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e axitinib • Kaitanni (cadonilimab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 33","initiation":"Initiation: 09/01/2023","start_date":" 09/01/2023","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-09-25"},{"id":"ce317297-3349-4270-b217-1644017fec7c","acronym":"PEComesCells","url":"https://clinicaltrials.gov/study/NCT05617105","created_at":"2022-11-15T15:57:32.452Z","updated_at":"2024-07-02T16:36:00.458Z","phase":"","brief_title":"Molecular Characterization of Perivascular Epithelioid Cell Tumors","source_id_and_acronym":"NCT05617105 - PEComesCells","lead_sponsor":"University Hospital, Strasbourg, France","biomarkers":" TFE3","pipe":"","alterations":" ","tags":["TFE3"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 12/01/2019","start_date":" 12/01/2019","primary_txt":" Primary completion: 12/01/2022","primary_completion_date":" 12/01/2022","study_txt":" Completion: 12/31/2022","study_completion_date":" 12/31/2022","last_update_posted":"2022-11-15"},{"id":"2c7aea1c-f022-40ea-9369-e14f70ce02b7","acronym":"UNICAB","url":"https://clinicaltrials.gov/study/NCT03685448","created_at":"2021-03-03T14:55:51.063Z","updated_at":"2024-07-02T16:36:17.039Z","phase":"Phase 2","brief_title":"ANZUP - Non-clear Cell Post Immunotherapy CABozantinib (UNICAB)","source_id_and_acronym":"NCT03685448 - UNICAB","lead_sponsor":"Australian and New Zealand Urogenital and Prostate Cancer Trials Group","biomarkers":" TFE3","pipe":" | ","alterations":" TFE3 translocation","tags":["TFE3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TFE3 translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Cabometyx (cabozantinib tablet)"],"overall_status":"Recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 04/11/2019","start_date":" 04/11/2019","primary_txt":" Primary completion: 10/30/2022","primary_completion_date":" 10/30/2022","study_txt":" Completion: 04/30/2024","study_completion_date":" 04/30/2024","last_update_posted":"2022-02-16"},{"id":"a1cd2191-9709-49a0-948c-443b92aa49a9","acronym":"UNISoN","url":"https://clinicaltrials.gov/study/NCT03177239","created_at":"2021-03-03T14:55:22.558Z","updated_at":"2025-02-25T14:26:25.805Z","phase":"Phase 2","brief_title":"Phase II Sequential Treatment Trial of Single Agent Nivolumab, Then Combination Ipilimumab + Nivolumab in Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma (ANZUP1602)","source_id_and_acronym":"NCT03177239 - UNISoN","lead_sponsor":"Australian and New Zealand Urogenital and Prostate Cancer Trials Group","biomarkers":" TFE3","pipe":" | ","alterations":" TFE3 translocation","tags":["TFE3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TFE3 translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 85","initiation":"Initiation: 10/19/2017","start_date":" 10/19/2017","primary_txt":" Primary completion: 12/31/2021","primary_completion_date":" 12/31/2021","study_txt":" Completion: 12/31/2022","study_completion_date":" 12/31/2022","last_update_posted":"2022-02-16"},{"id":"006154e1-1580-45ba-ae5b-88d5b8c35fa2","acronym":"BIONIKK","url":"https://clinicaltrials.gov/study/NCT02960906","created_at":"2021-03-03T14:55:07.666Z","updated_at":"2024-07-02T16:36:31.235Z","phase":"Phase 2","brief_title":"A BIOmarker Driven Trial With Nivolumab and Ipilimumab or VEGFR tKi in Naïve Metastatic Kidney Cancer","source_id_and_acronym":"NCT02960906 - BIONIKK","lead_sponsor":"Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie","biomarkers":" CD8 • PD-1 • LAG3 • TFE3 • TFEB","pipe":" | ","alterations":" TFEB translocation","tags":["CD8 • PD-1 • LAG3 • TFE3 • TFEB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TFEB translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • sunitinib • pazopanib"],"overall_status":"Completed","enrollment":" Enrollment 200","initiation":"Initiation: 05/31/2017","start_date":" 05/31/2017","primary_txt":" Primary completion: 02/15/2021","primary_completion_date":" 02/15/2021","study_txt":" Completion: 02/15/2021","study_completion_date":" 02/15/2021","last_update_posted":"2021-04-26"},{"id":"b21eff77-ea34-4bf9-8a05-bf6b186f811a","acronym":"","url":"https://clinicaltrials.gov/study/NCT02164838","created_at":"2021-01-19T08:44:50.753Z","updated_at":"2024-07-02T16:37:14.418Z","phase":"Phase 1","brief_title":"VEGF Receptor Tyrosine Kinase Inhibitor Axitinib in Children With Recurrent or Refractory Solid Tumors","source_id_and_acronym":"NCT02164838","lead_sponsor":"Children's Oncology Group","biomarkers":" TFE3","pipe":"","alterations":" ","tags":["TFE3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e axitinib"],"overall_status":"Completed","enrollment":" Enrollment 51","initiation":"Initiation: 09/01/2014","start_date":" 09/01/2014","primary_txt":" Primary completion: 10/19/2017","primary_completion_date":" 10/19/2017","study_txt":" Completion: 10/19/2017","study_completion_date":" 10/19/2017","last_update_posted":"2018-01-29"}]